Search Results
Your search for all items matches 1841 pages
Showing 101 - 150
Early Hormone Receptor–Positive/HER2-Negative Breast Cancer
This is Part 1 of Updates in Early-Stage Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Erika Hamilton, Michael Danso, and Komal Jhaveri discuss the management of early hormone receptor–positive/HER2-negative...
Management of De Novo Metastatic Estrogen Receptor–Positive Breast Cancer
This is Part 3 of Ovarian Function Suppression in Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Jame Abraham, Erin Roesch, and Azka Ali discuss the management of a patient with de novo metastatic estrogen...
Management of Recurrent Estrogen Receptor–Positive Breast Cancer
This is Part 2 of Ovarian Function Suppression in Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Jame Abraham, Erin Roesch, and Azka Ali discuss the management of a patient with recurrent estrogen...
Management of Stage I Breast Cancer
This is Part 1 of Ovarian Function Suppression in Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Jame Abraham, Erin Roesch, and Azka Ali discuss the management of stage I breast cancer. The patient is a...
Aki Morikawa, MD, PhD, on Brain Metastases: New Findings on Predictive Drug Testing
Aki Morikawa, MD, PhD, of the University of Michigan, and her team explored the use of patient-derived organoids from breast cancer brain metastases to evaluate drug sensitivities in a clinically meaningful time frame. Along with molecular profiling, she says, this method may further personalize...
Treatment of Relapsed/Refractory Triple-Negative Metastatic Breast Cancer
This is Part 3 of Novel Therapies for Advanced Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Aditya Bardia, Sara Tolaney, and Antonio C. Wolff discuss the treatment of relapsed/refractory triple-negative breast ...
Role of HER2 Expression in Hormone Receptor–Positive Metastatic Breast Cancer
This is Part 2 of Novel Therapies for Advanced Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Aditya Bardia, Sara Tolaney, and Antonio C. Wolff discuss the role of HER2 expression in hormone receptor–positive...
Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
This is Part 1 of Novel Therapies for Advanced Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Aditya Bardia, Sara Tolaney, and Antonio C. Wolff discuss the treatment of hormone receptor–positive, HER2-negative...
Lisa A. Carey, MD, and Javier Cortes, MD, PhD, on HER2-Positive Early Breast Cancer: Chemotherapy De-escalation Under Study in PHERGain Trial
Lisa A. Carey, MD, of the University of North Carolina at Chapel Hill, and Javier Cortes, MD, PhD, of the International Breast Cancer Center and Universidad Europea de Madrid, discuss phase II findings showing that one in three patients with HER2-positive early breast cancer may safely omit...
Lisa A. Carey, MD, and Dennis J. Slamon, MD, PhD, on Early Breast Cancer: Findings From the NATALEE Trial on Ribociclib Plus Endocrine Therapy
Lisa A. Carey, MD, of the University of North Carolina at Chapel Hill, and Dennis J. Slamon, MD, PhD, of the University of California, Los Angeles, discuss phase III study findings on ribociclib plus endocrine therapy as adjuvant treatment in patients with hormone receptor–positive, HER2-negative...
Jennifer A. Ligibel, MD, on Early Breast Cancer and Weight Loss: Results From the BWEL Trial
Jennifer A. Ligibel, MD, of Dana-Farber Cancer Institute, discusses a telephone-based weight loss intervention that induced clinically meaningful weight loss in patients with breast cancer who had overweight and obesity, across demographic and tumor factors. Additional tailoring of the intervention ...
Anita Mamtani, MD, on Axillary Dissection: For What Types of Breast Cancer Can It Be Avoided?
Anita Mamtani, MD, of Memorial Sloan Kettering Cancer Center, discusses study findings showing that axillary lymph node dissection was required by less than 2% of patients with cT1NO triple-negative or HER2-positive breast cancer having upfront surgery. There was no clear advantage of neoadjuvant...
Kari M. Rosenkranz, MD, on Breast Cancer: Impact of Breast Conservation on Local Recurrence
Kari M. Rosenkranz, MD, of Dartmouth Health, discusses findings from the ACOSOG Z11102 (Alliance) study, which showed that breast-conserving therapy is safe for patients with multiple ipsilateral breast cancer lesions, resulting in low recurrence rates. However, omitting adjuvant endocrine therapy...
Judy C. Boughey, MD, on Changes in Axillary Surgical Management: An I-SPY2 Analysis
Judy C. Boughey, MD, of the Mayo Clinic, discusses the decrease, over the past decade, of axillary lymph node dissection, especially in patients with node-positive breast cancer at diagnosis who had sentinel lymph node surgery after neoadjuvant chemotherapy. These findings are based on the records...
Lindsay L. Peterson, MD, on Exercise and Cancer Outcomes
Lindsay L. Peterson, MD, of the Washington University, St. Louis, discusses the value of physical activity in improving cancer prognosis, especially for patients with breast or colon cancer. Aerobic exercises and resistance training are recommended during and after treatment. Exercise may help...
Sherry X. Yang, MD, PhD, on Breast Cancer: New Recurrence Score Data From the TAILORx Trial
Sherry X. Yang, MD, PhD, of the National Cancer Institute, discusses findings from the TAILORx trial, which showed that, despite chemotherapy, patients with high recurrence scores continue to have a poor prognosis. This result suggests the need to develop new management strategies for patients with ...
Sherry X. Yang, MD, PhD, on Breast Cancer: New Recurrence Score Data From the TAILORx Trial
Sherry X. Yang, MD, PhD, of the National Cancer Institute, discusses findings from the TAILORx trial, which showed that, despite chemotherapy, patients with high recurrence scores continue to have a poor prognosis. This result suggests the need to develop new management strategies for patients with ...
Matthew P. Goetz, MD, on Breast Cancer: Interim Survival Results With Abemaciclib Plus a Nonsteroidal Aromatase Inhibitor
Matthew P. Goetz, MD, of Mayo Clinic, discusses recent data from the MONARCH 3 trial of patients with advanced hormone receptor–positive, HER2-negative breast cancer. The study, a second interim analysis, showed that longer overall survival was observed in both the intention-to-treat group as well...
Sean Khozin, MD, MPH, on Randomized Trials vs Real-World Evidence in Patients With Advanced Cancer
Sean Khozin, MD, MPH, of the Massachusetts Institute of Technology, discusses the “external validity deficits” of randomized clinical trials, which still involve only about 5% of adults with cancer, who may differ in important ways from real-world populations. Dr. Khozin describes the reasons for...
Prudence A. Francis, MD, on Premenopausal ER-Positive Breast Cancer: Past, Present, and Future
Prudence A. Francis, MD, of the Peter MacCallum Cancer Centre, discusses an update of the SOFT trial, which showed that adding ovarian function suppression (OFS) to adjuvant tamoxifen for premenopausal women with estrogen receptor (ER)-positive breast cancer reduces the risk of recurrence. OFS...
Andrea De Censi, MD, on Noninvasive Breast Cancer: 10-Year Results on Low-Dose Tamoxifen
Andrea De Censi, MD, PhD, of Italy’s E.O. Ospedali Galliera, discusses phase III findings showing that low-dose tamoxifen (so-called babytam) given for 3 years still significantly prevents recurrences from noninvasive breast cancer after a median of 7 years from treatment cessation. Babytam at 5...
Ann H. Partridge, MD, MPH, on Interrupting Breast Cancer Treatment to Attempt Pregnancy
Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, discusses results from the POSITIVE trial, which showed that a temporary interruption of endocrine therapy in women with hormone-responsive breast cancer in order to attempt pregnancy, does not affect short-term disease outcomes. The study ...
Mafalda Oliveira, MD, PhD, on Camizestrant vs Fulvestrant in Advanced Breast Cancer: New Phase II Results
Mafalda Oliveira, MD, PhD, of Spain’s Vall d’Hebron University Hospital and Institute of Oncology, discusses findings from the SERENA-2 trial, which compared the next-generation selective estrogen receptor degrader camizestrant to fulvestrant in patients with hormone receptor–positive,...
Marleen Kok, MD, PhD, on Early Breast Cancer: A Year in Review
Marleen Kok, MD, PhD, of the Netherlands Cancer Institute, discusses the most important advances in early breast cancer treatment during the past year for patients with triple-negative, HER2-positive, and estrogen receptor–positive disease. Dr. Kok also addresses long-term treatment toxicities and...
François-Clément Bidard, MD, PhD: Circulating Tumor Cells May Help Improve Outcomes in Metastatic Disease
François-Clément Bidard, MD, PhD, of the Institut Curie, discusses overall survival results from the STIC CTC trial. To guide the choice between chemotherapy and endocrine therapy for patients with metastatic, estrogen receptor–positive/HER2-negative breast cancer, researchers compared circulating...
Erica L. Mayer, MD, PhD, on Metastatic Breast Cancer: New Findings on Palbociclib After Prior CDK4/6 Inhibitor and Endocrine Therapy
Erica L. Mayer, MD, PhD, of Dana-Farber Cancer Institute, discusses findings from the PACE study of patients with endocrine- and CDK4/6 inhibitor–pretreated estrogen receptor–positive/HER2-negative metastatic breast cancer who were randomly assigned to fulvestrant alone; fulvestrant and...
Aditya Bardia, MD, MPH, on Elacestrant vs Standard-of-Care Endocrine Therapy in ER-Positive, HER2-Negative Breast Cancer
Aditya Bardia, MD, MPH, of Massachusetts General Hospital, discusses results from the phase III EMERALD trial, the first study to demonstrate improved progression-free survival vs standard of care in estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer with one to two prior lines ...
Per Karlsson, MD, PhD: New Data on Breast-Conserving Surgery, With or Without Radiotherapy
Per Karlsson, MD, PhD, of Sweden’s University of Gothenburg and the Sahlgrenska Comprehensive Cancer Center, discusses results from the POLAR study, which was a meta-analysis of three clinical trials of breast-conserving surgery with or without radiotherapy. POLAR is the first genomic classifier...
Joannie M. Ivory, MD, MSPH, and Lisa A. Carey, MD, on PAM50 Subtype and 21-Gene Recurrence Scores in Younger and Black Women With Breast Cancer
Lisa A. Carey, MD, and Joannie M. Ivory, MD, MSPH, both of the University of North Carolina at Chapel Hill, discuss the higher frequency and treatment implications of nonluminal A or high-risk tumors in Black and younger women. In this study, PAM50 and 21-gene assays revealed different demographic...
Mariana Chavez-MacGregor, MD, MSc, on Adjuvant Endocrine Therapy and Everolimus in HR-Positive, HER2-Negative Breast Cancer
Mariana Chavez-MacGregor, MD, MSc, of The University of Texas MD Anderson Cancer Center, discusses phase III results from the SWOG S1207 trial which was designed to evaluate the role of adjuvant everolimus in combination with adjuvant endocrine therapy among patients with high-risk, hormone...
Nicholas C. Turner, MD, PhD, on New Data on Capivasertib and Fulvestrant for Advanced Breast Cancer
Nicholas C. Turner, MD, PhD, of London’s Institute of Cancer Research and The Royal Marsden, discusses phase III results from the CAPItello-291 clinical trial, which showed that in patients with hormone receptor–positive, HER2-negative tumors resistant to aromatase inhibitors, adding the...
Joseph A. Sparano, MD, on Long-Term Breast Cancer Recurrence and Survival Data from TAILORx
Joseph A. Sparano, MD, of the Tisch Cancer Center at Mount Sinai Health System, discusses long-term clinical outcomes data that continue to show many women with early breast cancer can safely forgo chemotherapy, when guided by the 21-gene recurrence score result. The longer follow-up also showed...
Sara A. Hurvitz, MD: New Findings on Neoadjuvant Trastuzumab Deruxtecan and Anastrozole in Early-Stage Breast Cancer
Sara A. Hurvitz, MD, of the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, discusses phase II results from the TRIO-US B-12 TALENT study, which showed that patients with localized, hormone receptor–positive, HER2-low breast cancer who are treated with fam-trastuzumab...
Sara A. Hurvitz, MD, on Updated Survival Results on T-DXd vs T-DM1 in Metastatic Breast Cancer
Sara A. Hurvitz, MD, of the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, discusses phase III findings from the DESTINY-Breast03 study, which showed that second-line treatment with fam-trastuzumab deruxtecan-nxki (T-DXd) led to longer overall survival compared with...
Ruth O’Regan, MD, on Evaluation of the Breast Cancer Index in Early-Stage Breast Cancer
Ruth O’Regan, MD, of the University of Rochester Medical Center, discusses the Breast Cancer Index (BCI), a genomic assay that can assess the risk of late distant recurrence (5–10 years after diagnosis) of hormone receptor–positive, early-stage breast cancer. Among premenopausal women with this...
Yara Abdou, MD, on Race and Clinical Outcomes in the RxPONDER Breast Cancer Trial
Yara Abdou, MD, of the University of North Carolina, discusses results from the RxPONDER SWOG S1007 study, which showed that non-Hispanic Black women with hormone receptor–positive/HER2-negative breast cancer with one to three involved lymph nodes and a recurrence score of ≤ 25 have worse outcomes...
Julia Tchou, MD, PhD, on Triple-Negative Breast Cancer: Radiation Boost Plus Pembrolizumab
Julia Tchou, MD, PhD, of the University of Pennsylvania, discusses preliminary results of the phase Ib/II BreastVax study, which suggested a single preoperative pembrolizumab dose plus a tumor-targeting radiation boost may result in pathologic response in patients with early-stage triple-negative...
Regina Barragán-Carrillo, MD, on Breast Cancer Screening in the Transgender Population
Regina Barragán-Carrillo, MD, of Mexico’s National Institute of Medical Sciences and Nutrition Salvador Zubirán, discusses her findings showing that currently, physicians have limited knowledge about breast cancer screening in transgender patients. Were this topic addressed with widespread...
Marleen Kok, MD, PhD, on Triple-Negative Breast Cancer: Nivolumab Monotherapy or in Combination Therapy
Marleen Kok, MD, PhD, of The Netherlands Cancer Institute in Amsterdam, discusses the initial results from the BELLINI trial, which tested whether short-term preoperative nivolumab, either as monotherapy or in combination with low-dose doxorubicin or novel immunotherapy combinations, can induce...
Laurence Buisseret, MD, PhD, on Triple-Negative Breast Cancer: Chemoimmunotherapy With or Without an Anti-CD73 Antibody
Laurence Buisseret, MD, PhD, of Belgium’s Institut Jules Bordet, discusses phase II results from the SYNERGY trial, which tested first-line chemoimmunotherapy of durvalumab, paclitaxel, and carboplatin with or without the anti-CD73 antibody oleclumab in patients with advanced or metastatic...
Matteo Lambertini, MD, PhD, on Oncofertility Care for Young Women With Breast Cancer
Matteo Lambertini, MD, PhD, of the University of Genova and Policlinico San Martino Hospital, talks about why oncofertility counseling should now be considered mandatory in the care of young women with breast cancer. Among the treatments he recommends offering are oocyte/embryo cryopreservation (or ...
Antonio Marra, MD, on Metastatic Breast Cancer: Patterns of Genomic Instability and Their Effect on Treatment
Antonio Marra, MD, of Memorial Sloan Kettering Cancer Center, discusses a mutational signature analysis that reveals patterns of genomic instability linked to resistance to endocrine therapy with or without CDK4/6 inhibition in patients with estrogen receptor–positive/HER2-negative metastatic...
HER2-Positive Residual Disease
This is Part 4 of Updates in HER2-Positive Breast Cancer, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Carey K. Anders, Erika Hamilton, and Sara A. Hurvitz discuss the management of HER2-positive residual disease. The patient ...
HER2-Positive Early-Stage Breast Cancer
This is Part 3 of Updates in HER2-Positive Breast Cancer, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Carey K. Anders, Erika Hamilton, and Sara A. Hurvitz discuss the management of HER2-positive early-stage breast cancer....
Metastatic HER2-Positive Breast Cancer With Brain Metastases
This is Part 2 of Updates in HER2-Positive Breast Cancer, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Carey K. Anders, Erika Hamilton, and Sara A. Hurvitz discuss the management of metastatic HER2-positive breast cancer with ...
Metastatic HER2-Positive Breast Cancer
This is Part 1 of Updates in HER2-Positive Breast Cancer, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Carey K. Anders, Erika Hamilton, and Sara A. Hurvitz discuss the management of metastatic HER2-positive breast cancer. The ...
Etienne Brain, MD, PhD, on Breast Cancer: Adjuvant Endocrine Therapy With or Without Chemotherapy in Older Patients
Etienne Brain, MD, PhD, of the Institut Curie, discusses phase III findings from the Unicancer ASTER 70s trial, in which patients aged 70 or older with estrogen receptor–positive, HER2-negative breast cancer and a high genomic grade index received adjuvant endocrine therapy with or without...
Ann H. Partridge, MD, MPH, and Véronique Diéras, MD, on the Future of Cytotoxic Therapy: Antibody-Drug Conjugates?
Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, and Véronique Diéras, MD, of the Centre Eugène Marquis, discuss the many challenges posed by next-generation antibody-drug conjugates (ADCs). They include side effects such as hematotoxicity, gastrointestinal toxicities, and interstitial...
Ann H. Partridge, MD, MPH, and Ian E. Krop, MD, PhD, on Metastatic Breast Cancer: New Early Data on Patritumab Deruxtecan
Ann H. Partridge, MD, MPH, Dana-Farber Cancer Institute, and Ian E. Krop, MD, PhD, of Yale Cancer Center, discuss phase I/II findings on patritumab deruxtecan, a HER3-directed antibody-drug conjugate, in patients with HER3-expressing metastatic breast cancer. A pooled analysis showed antitumor...
Erika Hamilton, MD, on Metastatic Breast Cancer: Safety Follow-up Data on T-DXd vs T-DM1
Erika Hamilton, MD, of Sarah Cannon Research Institute at Tennessee Oncology, discusses phase III data from the DESTINY-Breast03 study, which reinforced the consistent safety profile of fam-trastuzumab deruxtecan-nxki (T-DXd) vs ado-trastuzumab emtansine (T-DM1) in patients with HER2-positive...
